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INTRODUCTION
Between 1999 and 2017 more than 400,000 people died due 
to an opioid-related death from both prescription and illicit 
use.1 Opioid overdose can occur as a result of accidental mis-
use of a legitimate prescription or as a result of intentional 
drug abuse, and it is among the most preventable public 
health threats facing the United States. Numerous initia-
tives and strategies have been proposed and implemented 
to help with the growing opioid issue. This report aims to 
provide insight into programs and products available in the 
United States which address mitigation strategies to pro-
mote safe and appropriate opioid prescribing.  
PRESCRIPTION DRUG MONITORING PROGRAM 
(PDMP)
The prescription drug monitoring program (PDMP) is an 
electronic database used to track controlled substance pre-
scriptions in each state. This database logs controlled drug 
prescription information including location, prescriber, and 
payment source. PDMP content, access, and utilization var-
ies from state to state; however, they share the common goal 
of tracking the use of potentially abused medications and 
utilizing the data to implement positive change. Prescrib-
ers and pharmacists access the PDMP to obtain information 
about a patient’s past medication history for controlled sub-
stances. The information included in a PDMP report allows 
for assessment of risks when issuing a new prescription, and 
also alerts the healthcare professional to recent prescrip-
tion opioid use.  This information may potentially serve 
as a deciding factor regarding opioid issuance, dosage, and 
duration of therapy.  In Rhode Island, prescribers must check 
the PDMP prior to prescribing a controlled substance to a 
patient for the first time and if the patient remains on ther-
apy it is recommended to check the PDMP every 3 months. 
For pharmacists in Rhode Island, it is recommended that 
they check the PDMP before dispensing a controlled pre-
scription to a patient for the first time and every 3 months 
thereafter, if the patient remains on long-term therapy. For 
both prescribers and pharmacists in Rhode Island it is also 
suggested to check the PDMP before prescribing or dispens-
ing a benzodiazepine or central nervous system-sedating 
medication.2 All 50 states currently utilize a PDMP system. 
(Figure 1). 
Figure 1. State Specific PDMP Requirements3
INITIAL OPIOID PRESCRIBING LIMITS BY STATE
States have begun restricting the total daily amount (mg) of 
opioid prescribed and quantities dispensed by pharmacies. 
Furthermore, more stringent restrictions have been placed 
when the opioid is prescribed for the first time, defined as 
the initial fill. The designation of ‘initial fill’ is determined 
by review of the PDMP records, and is typically defined by 
absence of a prescription for an opioid medication within a 
specified amount of time (i.e. preceding 30 or 60 days). Lim-
its range from a specific day supply to certain dosage units 
based on morphine milligram equivalents (MMEs), with the 
most common being a 7-day limit on initial fill of an opioid 
(Figure 2). Currently there are four states with a 3-day sup-
ply limit, three states with a 4-day supply limit, three states 
with a 5-day supply limit, 29 states with a 7-day supply 
limit, one state with a 14-day supply limit and nine states 
with no limit. Washington state law limits initial opioid 
prescriptions to no more than 30 dosage units and Oregon 
does not have a law that limits initial opioid prescriptions; 
however, the health authority recommends no more than a 
7-day trial. Maine has implemented a 100 MME/day limit, 
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Tennessee has implemented a 60 MME/day limit, Nevada 
has implemented a 90 MME/day limit, and Nebraska has 
implemented a 50 MME/day limit. Rhode Island defines 
their initial opioid prescribing limit as 30 MME per day for a 
maximum of 20 dosage units.5 
Although the states themselves are implementing limits 
on initial opioid fills, third-party payers may also limit initial 
fills to a pre-determined day supply. For example, Anthem, 
Inc. was among the first to limit patient’s first fill of opioids 
to a 7-day supply.6 Similarly, in 2018 CVS Caremark® also 
placed a 7-day supply limit on opioid prescriptions for an 
acute condition in which patients had not received opioids 
in the past 90 days.7 
NALOXONE ACCESSIBILITY
Pharmacologically, naloxone is a mu-opioid antagonist that 
displaces opioids that are bound at mu-opioid receptor sites. 
The physiological response to using this drug is immedi-
ate reversal of respiratory suppression and it is available in 
injectable and intranasal formulations. Almost all states 
have enacted Good Samaritan laws which protect citizens 
from legal implications when administering naloxone to a 
person in need. Good Samaritan laws are vital to protect 
both parties to ensure that patients receive access to care 
without concern for prosecution. The majority of states 
allow pharmacists to dispense naloxone to patients without 
a prescription if deemed fit, with the exception of Connecti-
cut, Idaho, Nebraska, and Oregon.8  
Eight states require co-prescribing of naloxone when a 
patient is prescribed an opioid, and under specific condi-
tions. For example, Arizona requires co-prescribing if the 
prescription issued exceeds 90 MME per day.9 In California, 
prescribers must offer a prescription for naloxone if the pre-
scription dosage for the patient is 90 or more MMEs per day, 
if the patient is concurrently using an opioid and benzodiaz-
epine, or if the patient is deemed as having an increased risk 
for overdose, which could include history of substance use 
disorder or returning to a high dose of medication when the 
patient is no longer as tolerant to that dose.10 New Mexico 
requires a naloxone prescription with any opioid prescrip-
tion exceeding a 5 day supply.11 In Rhode Island, co-prescrib-
ing is mandatory under 3 different scenarios: the patient is 
taking 50 or more MME per day, the patient is taking opioid 
and benzodiazepine concurrently, or when prescribing an 
opioid to a patient who has a history of opioid use disorder.5 
Vermont requires co-prescribing for patients on 90 or more 
MME per day, or if the patient is using an opioid and ben-
zodiazepine concurrently.12 Virginia requires co-prescribing 
if the patient’s daily MME exceeds 120, or if the patient is 
using an opioid and benzodiazepine concurrently.13 In Wash-
ington, prescribers must provide naloxone prescription when 
patient exceeds 50 MME per day.14 Florida requires naloxone 
to be co-prescribed when a patient is being treated with a 
Schedule II controlled substance for a traumatic injury with 
an Injury Severity Score of 9 or greater.15
ABUSE-DETERRENT FORMULATIONS
In 2017, more than 190 million opioid prescriptions were dis-
pensed from outpatient retail pharmacies; however of those, 
only about 3.8 million were written for an abuse-deterrent 
formulation (ADF).16 There are various mechanisms utilized 
to develop abuse-deterrent formulations: physical/chem-
ical barriers, agonist/antagonist combinations, aversion, 
delivery systems and new molecular entities or prodrugs.1,17 
Through the addition of agents such as gel or microspheres, 
physical/chemical barriers make it significantly more dif-
ficult to abuse a drug through injecting, chewing, crush-
ing, or snorting. There are currently seven abuse-deterrent 
opioids commercially available that utilize a physical/
chemical barrier formulation: Oxycontin®, Xtampza® ER, 
Morphabond™ ER, Hysingla™ ER, Arymo™ ER, ZoHydro® 
ER and RoxyBondTM IR (Table 1). In a review of 15 pre-mar-
ket studies, several ADFs showed improvement in endpoint 
scores when compared to their non-ADF counterparts. For 
example, Hysingla™ ER was shown to have a noticeable 
effect on the primary endpoints, drug-liking and likelihood 
of taking the drug again, when compared to hydrocodone, 
and the same can be said for Embeda® when compared to 
morphine sulfate.18
The mechanism of action for drugs that use an agonist/
antagonist formulation is such that the antagonist com-
ponent of the drug is released only when the drug is tam-
pered with, or taken via a non-oral route. The antagonist 
portion would displace the opioid agonist from the receptor, 
precipitating a withdrawal syndrome.
Figure 2. State Specific Opioid Prescribing Limits4
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MEDICARE PART D OPIOID  
OVERUTILIZATION POLICY
In 2019, Medicare implemented the Part D Opioid Overuti-
lization Policy. This policy is primarily focused on encour-
aging interdisciplinary collaboration and coordination in 
order to improve universal patient care across providers.19 
The primary areas of the policy include pharmacy alliance 
data, drug management programs, day supply limits, and 
opioid care coordination alerts. 
Pharmacy alliance data has three focal points: prevention 
of new cases of opioid overutilization, treatment of exist-
ing patients, and proper utilization of data. To prevent new 
cases, inappropriate prescribing must be identified, non-opi-
oid treatments must be promoted, and opioid use disorder 
diagnoses must be enhanced.  When treating existing pain 
patients, it has been recommended to offer a broad range of 
treatment options and to continuously implement updated 
practices. This data enables healthcare professionals to rec-
ognize opioid prescribing patterns and to monitor the effec-
tiveness and safety of treatment.20
Drug management programs (DMP) proactively aid the 
healthcare professional in identifying patients who may be 
at risk for misuse, abuse or potential overdose when pre-
scribed an opioid or benzodiazepine. Once identified, the 
Part D plan will contact the prescriber to determine medical 
necessity or potential risk for abuse. Medicare also deter-
mines if the patient may benefit from the implementation of 
a DMP to manage their prescriptions. Three major DMPs are 
patient-specific, point-of-sale claim edit (POS), pharmacy 
limitation, and prescriber limitation. Once a patient’s insur-
ance performs a case review and gives approval, POS can be 
used to limit the amount of frequently abused drugs that 
can be dispensed to a patient. Pharmacy limitation requires 
a patient to fill all prescriptions for frequently abused drugs 
at a specific pharmacy of their choosing. Prescriber limita-
tion requires a patient to obtain all medications of potential 
misuse from a sole provider, and contractual agreements 
between prescriber and patient may be utilized.   
The most recent Medicare policy also enacted an initial 
7-day supply limit for opioid- naïve patients and an opioid 
care coordination alert. The goal of a limiting day supply 
limit is to reduce long-term opioid use in patients who 
initially receive a prescription for treatment of acute pain. 
The opioid care coordination alert is intended to advise the 
pharmacist to consult the prescriber when a patient’s overall 
daily oral morphine equivalence exceeds 90 mg, to confirm 
appropriate use. 
FDA OPIOID ACTION PLAN
The FDA has recognized opioid abuse, dependence, and 
overdose as a public health crisis in the United States. In 
response, the Administration unveiled their Opioid Action 
Plan in 2016, which sought to establish advisory committees, 
propose appropriate regulatory activities and policy devel-
opment, with goals of improving the science of pain man-
agement and fostering communication and collaboration 
across fields.  
The FDA aimed to establish an expert advisory committee 
that would review new opioid drug applications that are not 
manufactured as abuse-deterrent formulations.  In addition, 
a pediatric advisory committee is intended to review and 
generate recommendations on labeling of opioids in regards 
to the pediatric population.21
Extended-release and long-acting opioid formulations 
are currently subject to a Risk Evaluation and Mitigation 
DRUG FORMULATION MECHANISM OF ACTION 
Oxycontin®  Physical/chemical barrier Oxycodone formulated using high- molecular- weight polyethylene oxide as the tablets outer 
coating to resist crushing. Also becomes a viscous gel to resist use via needles/IV. 
Xtampza® ER Physical/chemical barrier Oxycodone formulated with DETERx® technology, which incorporates oxycodone into fatty acid 
and wax microspheres resulting in slow diffusion- controlled drug release.  
MorphabondTM ER Physical/chemical barrier Morphine sulfate formulated with SentryBondTM technology, which retains extended- release 
properties if manipulated and becomes viscous to resist use via needles/IV. 
HysinglaTM ER Physical/chemical barrier Hydrocodone bitartrate formulated with ResistecTM, which hardens the tablet to increase 
difficulty of manipulation and becomes viscous when dissolved.
ArymoTM ER Physical/chemical barrier Morphine sulfate formulated using a polymer matrix to make it more difficult to cut, crush, grind 
or break. 
Embeda® Agonist/antagonist combo Morphine sulfate + naltrexone HCl. The naltrexone is stored at core of the pill in a sequestering 
membrane and is only released when capsule is manipulated. 
ZoHydro® ER Physical/chemical barrier A combination of 20% IR and 80% ER hydrocodone bitartrate formulated with BeadTek®, which 
forms a viscous gel if capsule is crushed or dissolved. 
RoxybondTM IR* Physical/chemical barrier Oxycodone formulated with SentryBondTM technology to make release lower and slower when 
manipulated. Also becomes viscous to resist use via needles/IV. 
Table 1.
*First and only immediate release abuse-deterrent formulation
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Strategy (REMS) program. The FDA expanded REMS pro-
grams to include not only product-specific materials, but 
also educational programs in pain management. Training 
and education has been expanded to include more members 
of the health care team, rather than solely prescribers. Imme-
diate release opioid labeling will expand to include any addi-
tional warning and safety information that is available, with 
the overall goal of this initiative being to promote safer pre-
scribing practices of immediate release opioid formulations.
The development of ADFs has become a major area of 
interest in the pharmaceutical industry. The issue still per-
sists, however, that the currently available ADFs are brand 
name products. This may pose a significant financial burden 
which limits their access for use.  In response to the need to 
increase accessibility of opioid ADFs, the FDA has issued 
a high priority draft guidance to encourage the approval of 
generics.  
The availability of naloxone varies from state to state. As 
outlined in the FDA’s 2018 Strategic Policy roadmap, over-
the-counter (OTC) naloxone is being reviewed to allow for 
expanded access.22 States such as Rhode Island have approved 
the purchase of OTC naloxone and data from 2016-2018 cor-
related the reduction in opioid-overdose related deaths to 
the increased availability of naloxone during this time.23
CURRENT USE OF STRATEGIES
The use of the PDMP remains the most common mitiga-
tion strategy in the US. Naloxone accessibility has also 
improved; however, further efforts are needed to increase 
access across all 50 states. Most states are implementing 
prescribing limits on initial opioid prescription fill quanti-
ties. Lastly, affordability and further access to ADF products 
is needed to aid in combating the opioid crisis. (Figure 3) 
While no single approach will be sufficient to mitigate opi-
oid risks while balancing appropriate use, a strategy that 
considers multiple possible approaches is needed to improve 
the health care landscape regarding opioid safety. 
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